Outcome of Organ Sparing Trimodality Treatment of Muscle Invasive Bladder Cancer
Published: 2023-10-25
Page: 98-104
Issue: 2023 - Volume 6 [Issue 1]
Rokonuzzaman S. M. *
Department of Radiation Oncology, Combined Military Hospital (CMH), Dhaka, Bangladesh.
Ali Yousuf
Department of Radiation Oncology, Combined Military Hospital (CMH), Dhaka, Bangladesh.
Sultana Nazat
Department of Radiation Oncology, Combined Military Hospital (CMH), Dhaka, Bangladesh.
*Author to whom correspondence should be addressed.
Abstract
Background: Radical cystectomy leftovers the fundamental healing approach for muscle-invasive bladder cancer. However, there has been notable success in preserving the bladder through trimodality treatment, utilizing a mixture of the most significant Trans urethral resection of bladder tumor (TURBT) and chemo-radiation therapy.[1] The contemporary landscape of oncologic interventions is progressively inclined towards preserving organ function, optimizing functional outcomes, and upholding treatment effectiveness and quality of life (QoL). This Trimodality Therapy (TMT) encompasses Maximal TURBT, Radiation therapy, and Chemotherapy. Aim of the study was to observe the tumor response to treatment by concomitant Chemo-Radiation (TMT).
Methods: A quasi-experimental study of 47 patients with muscle-invasive bladder cancer who were ineligible for radical cystectomy was conducted from January 2012 to January 2019. Patients received induction chemotherapy with gemcitabine and cisplatin and radiotherapy with volumetric or intensity-modulated arc therapy. The median follow-up was 40 months, and the 5-year and recurrence-free survival rates were 59% and 50%, respectively.
Results: Trimodality therapy, combining surgery, radiation, and chemotherapy, demonstrated promising outcomes for muscle-invasive bladder cancer (MIBC) treatment. The 5-year Overall Survival (OS) rate reached 59%, surpassing the typical <50% rate. Disease-free survival (DFS) at 5 years was 50%. Completion rates varied among studies (NCI CTAE 21.30%, Our Study 12.70%, RTOG 6%), attributed to study criteria and resources. Despite differences, all contribute valuable MIBC treatment data. These findings endorse trimodality therapy as a standard MIBC treatment, offering optimal survival prospects.
Conclusion: Trimodality bladder preservation treatment presents a viable substitute for radical cystectomy for individuals who seek to maintain their bladder.
Keywords: Radiation, chemo-radiation, trimodality therapy, muscle-invasive bladder cancer, TURBT
How to Cite
Downloads
References
Kamran SC, Jason A. Efstathiou. Current state of personalized genitourinary cancer radiotherapy in the era of precision medicine. 2021;11. Available:https://doi.org/10.3389/fonc.2021.675311
The Global Cancer Observatory. International Agency for Research on Cancer. World fact sheets. Available:http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
(Accessed on February 18, 2021).
VanderWalde NA, Chi MT, Hurria A, et al. Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit. World J Urol. 2016; 34:3-11.
Hajime Tanaka, Toshiki Kijima, Yasuhisa Fujii. Bladder preservation therapy in muscle-invasive bladder cancer: Current evidence and future perspectives. AME Med J. 2020;5:16,1-15.
Witjes JA, Comperat E, Cowan NC, et al. European Association of Urology guidelines on muscle-invasive bladder cancer: 2020 update. PMID: 32360052. DOI: 10.1016/j.eururo.2020.03.055
Kamoun A, de Reyniès A, Allory Y, et al. Bladder cancer molecular taxonomy group. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020;77(4):420-433. DOI: 10.1016/j.eururo.2019.09.006. Epub 2019 Sep 26. PMID: 31563503; PMCID: PMC7690647
Al-Adra DP, Al-Haddad MA, Amarin AA, Al-Omari MA, Abu-Hijleh MS. Complete response following transurethral resection of bladder tumor in patients with visible tumor remnants: A single-center experience. Urol Int. 2023;100(1): 105-110. DOI: 10.1159/000514269
Witjes JA, Feikema AAH. Organ-sparing strategies in muscle-invasive bladder cancer. Cancer Manag Res. 2021 Oct 13;13:7833-7839. DOI: 10.2147/CMAR.S294099. PMID: 34675678; PMCID: PMC8520819.
Witjes JA, Feikema AAH. Organ-sparing strategies in muscle-invasive bladder cancer. Cancer Manag Res. 2021;13: 7833-7839. DOI: 10.2147/CMAR.S294099. PMID: 34675678; PMCID: PMC8520819.
Dall'Era MA, Cheng L, Pan CX. Contemporary management of muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2012;12(7):941-50. DOI: 10.1586/era.12.60. PMID: 22845409; PMCID: PMC3494992.
Pechacova Z, Lohynska R, Pala M, Drbohlavova T, Korinek T. Impact of comorbidity scores and lifestyle factors in curative radiotherapy in laryngeal cancer. Strahlentherapie und Onkologie. 2023; 1-0.
Vanella L, Barbagallo I, Tibullo D, Forte S, Zappalà A, Volti GL. The non-canonical functions of the heme oxygenases. Oncotarget. 2016;7(42):69075.
Royce TJ, Liu Y, Milowsky MI, Efstathiou JA, Jani AB, Fischer-Valuck B, Patel SA. Trimodality therapy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Clinical genitourinary cancer. 2021;19(4): 362-8.
Royce TJ, Liu Y, Milowsky MI, Efstathiou JA, Jani AB, Fischer-Valuck B, Patel SA. Trimodality therapy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Clinical genitourinary cancer. 2021;19(4):362-8.
Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ. Bladder preservation in the treatment of muscle‐invasive bladder cancer (MIBC): A review of the literature and a practical approach to therapy. BJU international. 2013;112(1):13-25.
El-Taji OM, Alam S, Hussain SA. Bladder sparing approaches for muscle-invasive bladder cancers. Current Treatment Options in Oncology. 2016;17:1-4.